Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Post-Transplantation Hypomagnesemia as a Predictor of Survival Among the Kidney Transplant Population.
T. Hod, B. Patibandla, A. Chandraker.
Transplant Research Center, Brigham and women's hospital, Boston, MA.
We have previously shown a robust relationship between low magnesium in the first year post-transplant and better long-term kidney allograft function. Given this somewhat counterintuitive…
2016 American Transplant Congress
Psychosocial Factors Associated with Medication Adherence Based on Self Reports in Kidney Allograft Recipients: Baseline Findings from the PRIMA (ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application) Study.
A. Han,¹ C. Choi,¹ S.-Y. Kim,¹ S. Cho,¹ M.-J. Cho,¹ C. Lee,¹ S. Ahn,¹ S.-I. Min,¹ S.-K. Min,¹ I. Jung,¹ S. Kim,² M. Park,³ J. Ha.^1,3
¹Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea; ²Department of Surgery, Myongji Hospital, Goyang-si, Gyeonggi-do, Republic of Korea; ³Korean Organ Donation Agency, Seoul, Republic of Korea.
Background. We have assessed the prevalence of medication nonadherence after kidney transplantation and investigated its psychosocial correlates, as a part of the PRIMA study, an…
2016 American Transplant Congress
Kidney Waitlist Management with Lean Six Sigma.
V. Arelin,¹ J. Schaefer,³ H. Haller,¹ I. Ackermann,² H. Schrem.²
¹Nephrology and Hypertension, Medical School Hanover, Hannover, Germany; ²Transplant and Viceral Surgery, Medical School Hanover, Hannover, Germany; ³Center for Information Technology, Medical School Hanover, Hannover, Germany.
BackgroundLean thinking is a bundle of concepts, methods and tools for organizing human activities in organizations. It attempts to eliminate the underlying unnecessary waste in…
2016 American Transplant Congress
Predictors of Patient Uncertainty Regarding Treatment Options Among End Stage Renal Disease Patients Evaluated for Kidney Transplantation.
L. McPherson,¹ M. Basu,¹ S. Pastan,¹ S. Mohan,² M. Wolf,³ J. Gander,¹ R. Patzer.¹
¹Emory University, Atlanta, GA; ²Columbia University, New York City, NY; ³Northwestern University, Chicago, IL.
Background: Although kidney transplantation (KTx) provides a significant survival benefit over long-term dialysis, many end stage renal disease (ESRD) patients are uncertain or conflicted about…
2016 American Transplant Congress
Evolution of Body Composition and Associations to Glucose Metabolism During the First Year After Kidney Transplantation.
M. von Düring,¹ A. Hartmann,^1,2 J. Bollerslev,^2,4 A. Åsberg,^1,3 K. Godang,⁴ I. Eide,¹ D. Dahle,¹ T. Jenssen.^1,5
¹Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ³School of Pharmacy, University of Oslo, Oslo, Norway; ⁴Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁵Metabolic and Renal Research Group, University of Tromsø, Tromsø, Norway.
Background. The evolution and association between body composition and glucose haemostasis after kidney transplantation has not been elucidated.Methods. We investigated 150 consecutive patients without suspected…
2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
2016 American Transplant Congress
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.
J. de Fijter,¹ H. Holdaas,¹ M. Seelen,¹ S. Sundar,¹ F. Bemelman,¹ P. Lopez,² J. Aguilar,² P. Bernhardt,² Z. Wang,³ J. Cruzado,¹ M. van der Giet.¹
¹ELEVATE study group, Leiden, Netherlands; ²Novartis, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover, NJ.
Background: Proteinuria is a biomarker which helps in predicting graft outcomes in kidney transplant recipients (KTxRs). The ELEVATE study was designed to determine whether an…
2016 American Transplant Congress
Effect of mTOR Inhibitors on the Risk of Cancer Development After Kidney Transplantation in Chinese Population.
C.-C. Kao,¹ J.-S. Liu,² M.-H. Lin,² F.-C. Chang,¹ Y.-C. Lin,¹ H.-H. Chen,¹ T.-W. Chen,¹ C.-C. Hsu,² M.-S. Wu.¹
¹Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; ²Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.
Introduction The mTOR inhibitor is an immunosuppressive drug used in kidney transplantation. Whether the mTOR inhibitors is associated with reduced risk of cancer development in…
2016 American Transplant Congress
Pregnancy Excludes Women from Successful Living Donor Transplantation.
P. Porrett,¹ B. Bromberger,² S. Hashmi,¹ A. Morrison,¹ D. Sawinski.³
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Surgery, Columbia University, New York, NY; ³Medicine, University of Pennsylvania, Philadelphia, PA.
INTRODUCTION Pregnancy-induced sensitization (PIS) is a barrier to the transplantation of women and contributes significantly to gender disparity in transplantation. We hypothesized that this barrier…
2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
S. Pol,¹ A. Aghemo,² L. Lin,³ R. Hyland,³ C. Yun,³ J. Spellman,³ M. Natha,³ D. Brainard,³ J. McHutchison,³ M. Bourlière,⁴ M. Peck-Radosavljevic,⁶ M. Michael,⁵ M. Colombo.²
¹Hopital Cochin, Paris, France; ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³Gilead Sciences Inc, Foster City; ⁴Hôpital Saint Joseph, Marseilles, France; ⁵Hannover Medical School, Hannover, Germany; ⁶Medical University of Vienna, Vienna, Austria.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…